Can I Take Quercetin With Retatrutide? A Women's Health Guide

The Short Answer on Quercetin and Retatrutide

Taking quercetin while you are on retatrutide is not proven dangerous, but it is also not proven safe. The gap between those two statements matters. Quercetin is a flavonoid sold widely as an immune-support and anti-inflammatory supplement, and it has a well-documented ability to inhibit CYP3A4, one of the liver's main drug-metabolizing enzymes. Retatrutide, a triple agonist of GIP, GLP-1, and glucagon receptors, is still in late-stage clinical trials, and its full cytochrome P450 interaction profile has not been published in a peer-reviewed pharmacokinetic study as of mid-2025.

That combination of "supplement with known enzyme inhibition" plus "drug with incompletely characterized metabolism" is a reason for caution, not panic. This article walks through what is known, what is extrapolated, and what you should discuss with your prescriber.

What Is Retatrutide and Why Are Women Interested in It?

Retatrutide is a once-weekly injectable peptide that simultaneously activates three receptors: glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). In the Phase 2 TRIUMPH trial published in the New England Journal of Medicine, participants receiving the highest dose (12 mg) lost a mean of 24.2% of body weight over 48 weeks, a figure that exceeds any currently approved weight-loss drug.

Why women across life stages are seeking it

Women carry a disproportionate burden of obesity-related conditions. PCOS affects an estimated 6 to 12% of women of reproductive age and is strongly linked to insulin resistance and weight gain. Perimenopause brings a shift in fat distribution toward visceral adiposity even without caloric change. Postmenopausal women face accelerated metabolic risk as estrogen declines.

Retatrutide's glucagon receptor activity is particularly interesting for women with PCOS because glucagon physiology interacts with insulin resistance in ways that differ between sexes. Women with PCOS show exaggerated glucagon responses relative to matched controls, as reviewed in Fertility and Sterility. Whether retatrutide's glucagon agonism proves net beneficial or adds complexity in this population is a question the Phase 3 trials have not yet fully answered. This is an evidence gap, and you deserve to know it.

Retatrutide's regulatory status

Retatrutide is not FDA-approved. It is manufactured by Eli Lilly and is currently in Phase 3 development. Women accessing it are doing so through clinical trials or, in some cases, compounding pharmacies. The FDA has issued guidance noting that compounded versions of investigational drugs raise additional quality and safety concerns.

What Is Quercetin and Why Do Women Take It?

Quercetin is a polyphenolic flavonoid found in onions, capers, and apples. As a supplement it is sold at doses ranging from 250 mg to 1,000 mg per day. Women take it for several reasons:

• Anti-inflammatory support, including for conditions like endometriosis and autoimmune thyroid disease
• Immune modulation (especially post-COVID fatigue protocols)
• PCOS-related insulin sensitization. A 2021 randomized controlled trial in Phytotherapy Research found that 1,000 mg/day quercetin for 12 weeks reduced fasting insulin and free testosterone in women with PCOS compared with placebo, though the sample was only 84 participants
• Mast cell stabilization in women with histamine intolerance, a condition more prevalent in the estrogen-dominant phases of the menstrual cycle
• General antioxidant supplementation during perimenopause

Quercetin's popularity has grown rapidly, and many women already take it before they begin a GLP-1 or triple-agonist medication. That sequencing matters for interaction risk.

The Core Interaction Concern: CYP3A4 Inhibition

How CYP3A4 works in drug metabolism

CYP3A4 is responsible for metabolizing roughly 30 to 50% of all clinically used drugs. When an inhibitor blocks CYP3A4, drugs metabolized by that enzyme may accumulate to higher-than-expected plasma concentrations, which can amplify both therapeutic effects and adverse effects.

Quercetin as a CYP3A4 inhibitor

Quercetin inhibits CYP3A4 in both in vitro assays and, to a lesser degree, in vivo human pharmacokinetic studies. A 2010 study in Drug Metabolism and Disposition showed that quercetin at concentrations achievable with standard supplementation doses inhibited CYP3A4 with an IC50 in the low-micromolar range. A 2016 systematic review in the British Journal of Clinical Pharmacology found clinically meaningful increases in area under the curve (AUC) for several CYP3A4-substrate drugs when co-administered with quercetin, particularly for drugs with low oral bioavailability.

Quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter that acts as a gatekeeper at the gut wall, liver, and blood-brain barrier. P-gp and CYP3A4 often work together to limit drug absorption; inhibiting both simultaneously can magnify drug exposure more than inhibiting either alone.

Where retatrutide fits in this picture

Here is the honest answer: Eli Lilly has not published a dedicated drug-interaction pharmacokinetic study for retatrutide as of mid-2025. The Phase 2 trial excluded participants on drugs with known CYP3A4 interactions, but the trial report does not specify whether retatrutide itself is a CYP3A4 substrate. Retatrutide is a 25-amino-acid acylated peptide. Large peptides are typically metabolized by proteolytic degradation rather than by hepatic CYP enzymes, which would reduce (but not eliminate) the relevance of CYP3A4 inhibition.

The WomanRx clinical framework for evaluating this combination uses three questions:

1. Is retatrutide a CYP3A4 substrate? Likely low to minimal, based on its peptide structure, but not confirmed in published data. This is extrapolated, not directly studied.
2. Does quercetin alter GLP-1 receptor signaling directly? Quercetin has demonstrated GLP-1 secretagogue activity in vitro, meaning it may independently stimulate GLP-1 release from gut L-cells. Combining it with a GLP-1 receptor agonist could theoretically produce additive nausea, vomiting, or delayed gastric emptying, though clinical evidence for this pharmacodynamic overlap is absent.
3. Does quercetin's antihistamine-like activity interact with retatrutide's tolerability profile? Quercetin stabilizes mast cells and reduces histamine release. Retatrutide's GIP receptor activity may modulate mast cell behavior. The interaction here is speculative, but worth monitoring in women who already have histamine intolerance.

Sex-Specific Physiology: Why This Interaction May Play Out Differently in Women

Women metabolize drugs differently from men across virtually every phase of pharmacokinetics, and these differences are not trivial. CYP3A4 activity is approximately 20 to 37% higher in women than in men, which means women generally clear CYP3A4-substrate drugs faster at baseline. Paradoxically, that also means that when a CYP3A4 inhibitor like quercetin is introduced, women may experience a proportionally larger relative reduction in clearance.

Menstrual cycle effects

Estrogen itself modulates CYP3A4. CYP3A4 activity rises in the luteal phase when progesterone is high. If you take quercetin intermittently (as some women do, cycling with their menstrual symptoms), the degree of CYP3A4 inhibition fluctuates across the month. This creates variable drug exposure, which is particularly problematic for a medication like retatrutide that is dosed weekly to maintain stable plasma levels.

Perimenopause and postmenopause

In perimenopause, estrogen fluctuations are unpredictable, and CYP3A4 activity becomes less consistent. Postmenopausally, CYP3A4 activity tends to be lower at baseline than in reproductive-age women. A postmenopausal woman on a CYP3A4 inhibitor may accumulate a co-administered CYP3A4-substrate drug more than a 30-year-old would, even at the same dose. Sex and hormonal status are rarely accounted for in drug-interaction databases, and that is a gap you should know about.

Thyroid function

Many women who take quercetin are also on levothyroxine for hypothyroidism. Quercetin may reduce the absorption of levothyroxine, as noted in a 2021 case report in Thyroid. Retatrutide's delayed gastric emptying effect (via GLP-1 receptor agonism) independently alters the absorption timing of oral medications including levothyroxine. Stacking both effects without adjusting levothyroxine timing could lead to under-treatment of hypothyroidism.

Pregnancy, Lactation, and Contraception: Required Reading

Retatrutide is contraindicated in pregnancy. This is not a relative precaution; it is an absolute one, based on the class-wide teratogenicity signal seen with GLP-1 receptor agonists in animal studies. The FDA pregnancy labeling for the approved GLP-1 drug semaglutide (Ozempic/Wegovy) carries a warning that the drug should be discontinued at least 2 months before a planned pregnancy due to its long half-life. Retatrutide has a similarly extended half-life. The ACOG has noted that GLP-1 receptor agonists as a class should not be used in pregnancy based on current data.

If you are of reproductive age and sexually active, you must use reliable contraception while on retatrutide. The drug's weight-loss effect may restore ovulation in women with PCOS or obesity-related anovulation, increasing pregnancy risk precisely when a woman might not expect it.

Quercetin in pregnancy: Animal studies show mixed signals. High-dose quercetin has demonstrated genotoxic effects in some rodent models. A 2021 review in Nutrients found insufficient human data to recommend quercetin supplementation in pregnancy. Avoid it during pregnancy unless specifically directed by your OB-GYN.

Lactation: No published human lactation pharmacokinetic data exists for retatrutide. For semaglutide, the FDA label states that it is "not known" whether the drug passes into breast milk. Given the molecular size of retatrutide and its acylated peptide structure, transfer into breast milk may be limited, but gut absorption by the infant cannot be ruled out. Quercetin is a dietary constituent found in breast milk at low concentrations through food intake, but supplemental doses have not been studied in nursing women. Avoid supplemental quercetin while breastfeeding unless your provider has specifically reviewed the risk.

Who This Combination Is Right For vs. Not Right For

Women who may consider both with prescriber approval

• Women with PCOS and insulin resistance who are not pregnant and not trying to conceive, under close metabolic monitoring
• Postmenopausal women with documented inflammatory conditions where quercetin has shown benefit (e.g., osteoarthritis, cardiovascular risk reduction), provided no CYP3A4-sensitive drugs are in their regimen
• Women already enrolled in a retatrutide clinical trial who have disclosed quercetin use to the trial team

Women who should avoid combining them

• Anyone pregnant, trying to conceive, or not using reliable contraception
• Women in perimenopause with variable estrogen levels and no recent CYP3A4 interaction review
• Women on concomitant medications that are narrow-therapeutic-index CYP3A4 substrates (cyclosporine, tacrolimus, some statins, certain anticoagulants)
• Women with hypothyroidism on levothyroxine who have not adjusted their levothyroxine timing

Dose Timing, Monitoring, and Practical Guidance

If your prescriber reviews your full medication list and concludes the combination is acceptable for you, these are the practical considerations:

Timing quercetin around retatrutide injection day: Retatrutide is injected once weekly and reaches peak plasma concentration within 24 to 48 hours. Quercetin's CYP3A4 inhibition effect is present as long as the supplement is circulating (quercetin has a plasma half-life of roughly 3.5 to 7 hours after a single dose). Because retatrutide is a weekly drug, day-of-dose separation from quercetin is unlikely to meaningfully reduce any interaction; the more relevant question is whether you take quercetin daily or intermittently.

What to monitor:

• GI symptoms (nausea, vomiting, delayed gastric emptying) may intensify if quercetin's GLP-1 secretagogue effect adds to retatrutide's GLP-1 activity
• Blood glucose, especially if you are on metformin or insulin alongside retatrutide. Additive insulin-sensitizing effects are possible
• Thyroid function if you are on levothyroxine, with a repeat TSH 6 to 8 weeks after adding or removing quercetin
• Blood pressure, since quercetin has modest antihypertensive effects and retatrutide reduces weight, which itself lowers blood pressure

Dose of quercetin that matters: Most in vitro interaction data uses concentrations corresponding to 500 mg to 1,000 mg oral doses. Lower doses (250 mg/day) may produce less CYP3A4 inhibition, though the clinical threshold in women has not been studied in an interaction-specific trial.

What the Evidence Gap Means for You

Women have been consistently under-represented in drug metabolism studies. The NIH Revitalization Act of 1993 required inclusion of women in NIH-funded trials, but pharmacokinetic sub-studies with sex-stratified CYP data remain rare. No published study has examined the quercetin-retatrutide combination specifically in women. This article synthesizes data from:

• Retatrutide Phase 2 pharmacokinetic data (published)
• General peptide drug metabolism literature
• Quercetin CYP3A4 inhibition data (multiple peer-reviewed studies)
• Sex differences in CYP3A4 activity (well-established)
• GLP-1 secretagogue activity of quercetin (in vitro only)

Everything beyond that is extrapolated. You deserve an honest accounting of where the certainty ends.

What to Tell Your Prescriber

Bring this list to your next appointment if you take or are considering quercetin alongside retatrutide:

• The brand and dose of quercetin you are using (doses vary widely by product)
• Whether you take it daily or cyclically
• All other supplements, especially those with CYP3A4 activity (grapefruit, St. John's wort, berberine, resveratrol)
• Your thyroid status and current levothyroxine dose if applicable
• Your menstrual or hormonal status (reproductive age, perimenopause, postmenopause, on hormonal contraception)
• Whether you are using contraception reliably

Your prescriber can then cross-reference your full medication list against the FDA Drug Interaction Database and make a personalized recommendation.